Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Triazole-derivative anticonvulsant (sodium channel modulator)

Banzel (rufinamide)

An approved treatment for Lennox-Gastaut Syndrome.

FDA Approved (2008)by Eisai Inc.
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2008

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Rufinamide wherever you encounter it, plus the key facts at a glance.

Generic name
Rufinamide
Brand name
Banzel
Development code
E2080
Drug class
Triazole-derivative anticonvulsant (sodium channel modulator)
Manufacturer
Eisai Inc.
How it's taken
By mouth: Banzel tablets or oral suspension, twice a day with food

Rufinamide is a seizure medicine approved as an add-on treatment for seizures associated with Lennox-Gastaut syndrome in children 1 year and older and in adults[1].

  • Eisai sells it as Banzel film-coated tablets (200mg and 400mg) and Banzel oral suspension (40mg/mL)[1].
  • The FDA approved the tablets on November 14, 2008, the oral suspension on March 3, 2011, and the extension to children 1 to under 4 years old on February 12, 2015[2][3][5].
  • The label carries no boxed warning, and rufinamide is not used in people with familial short QT syndrome, an inherited heart rhythm condition[1].
  • Generic rufinamide tablets and oral suspension are FDA approved[4].
Follow Banzel by email

We'll email you when Banzel's FDA label changes, when the FDA acts on it, and when new trials for Lennox-Gastaut Syndrome open. Unsubscribe anytime.

You'll get, for Lennox-Gastaut Syndrome:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Rufinamide fits

Rufinamide (Banzel) is a sodium channel seizure medicine approved since 2008 as an add-on treatment for seizures associated with Lennox-Gastaut syndrome, and since February 2015 for children as young as 1 year[1][2][5].

  • Lennox-Gastaut care usually combines several seizure medicines, according to NORD, and the rufinamide trial added it to 1 to 3 seizure medicines people were already taking[14][1].
  • Other medicines labeled for Lennox-Gastaut seizures include clobazam (Onfi, Sympazan), cannabidiol (Epidiolex), fenfluramine (Fintepla), lamotrigine, topiramate, clonazepam (Klonopin) and felbamate (Felbatol)[8][9][10][13][12][11][15].
  • The Banzel label reports 1 placebo-controlled trial, and ClinicalTrials.gov lists no trial comparing rufinamide with a named Lennox-Gastaut medicine; the only active-controlled study, in children 1 to under 4, compared it with any seizure medicine the doctor chose[1][7].
  • Valproate, which NORD describes as generally considered the first-line Lennox-Gastaut medicine, can raise rufinamide levels by up to 70% in children, which is why the Banzel label starts people taking valproate on a lower rufinamide dose[14][1].
  • Anyone considering rufinamide can ask their neurologist how it would fit with their current seizure medicines, and whether any family history of heart rhythm problems such as familial short QT syndrome matters before starting.

How Rufinamide works

Lennox-Gastaut syndrome causes several seizure types, including drop seizures (tonic or atonic seizures that can make a person fall) and atypical absence seizures (staring spells). Rufinamide is a triazole derivative, and the label says it is chemically unrelated to other marketed seizure medicines[1].

Lab studies suggest it works mainly on sodium channels, the pores nerve cells use to fire electrical signals: it keeps the channels in their resting, inactive state longer, which limits the rapid repeated firing behind seizures; the label says the exact mechanism is unknown[1]. The body breaks rufinamide down mostly through enzymes called carboxylesterases rather than the liver's cytochrome P450 system, and the breakdown products are inactive[1].

Rufinamide's half-life is about 6-10 hours, which is why it is taken twice a day, and food raises the amount absorbed by about 34%, which is why the label says to take it with food[1]. Valproate slows the clearance of rufinamide, while carbamazepine, phenytoin, phenobarbital and primidone speed it up[1].

Side effects and safety

What patients report
Label warnings
  • Suicidal thoughts or behavior. a warning shared by all seizure medicines; watch for new or worse depression, unusual mood or behavior changes, or thoughts of self-harm
  • Sleepiness, dizziness and coordination problems. in the Lennox-Gastaut trial, sleepiness affected 24% on rufinamide against 13% on placebo, and unsteady walking (ataxia) 5.4% against 0%; no driving or dangerous machinery until the effect is known
  • QT shortening. rufinamide shortens the QT interval on an ECG; not used in familial short QT syndrome, and used with caution alongside other medicines that shorten the QT interval
  • DRESS (multiorgan hypersensitivity). fever, rash, swollen glands or facial swelling with organ involvement such as hepatitis, which can be fatal; in trials every case was in a child under 12 within 4 weeks of starting; rufinamide is stopped if DRESS is suspected
  • Stopping suddenly. can bring on more seizures or status epilepticus; in trials the dose was lowered by about 25% every 2 days
  • Status epilepticus. in the Lennox-Gastaut trial, 3 of 74 people on rufinamide (4.1%) had episodes that could be described as status epilepticus, against none of 64 on placebo
  • Low white blood cell count. leukopenia in 3.7% on rufinamide against 1.2% on placebo across all controlled trials
  • Hormonal birth control. rufinamide can make hormonal contraceptives less effective, so the label recommends an added non-hormonal method
Most common in trials
SleepinessVomitingHeadacheTirednessDizzinessNausea
What gets monitored
  • Watching for sleepiness, dizziness and unsteady walking, most of all with alcohol or other sedating medicines
  • Watching for fever with rash or swollen glands; in trials every DRESS case began within 4 weeks of starting
  • Watching for mood changes or thoughts of self-harm
  • Watching for seizures becoming more frequent or worse
Report a suspected reaction to Eisai Inc. at 1-888-274-2378 or FDA MedWatch at 1-800-FDA-1088, or to the FDA at 1-800-FDA-1088.
In context

The Banzel label carries no boxed warning[1]. In the placebo-controlled Lennox-Gastaut trial of 74 people on rufinamide and 64 on placebo, sleepiness affected 24% against 13% and tiredness 10% against 8%, while unsteady walking (ataxia) affected 5.4%, dizziness 2.7% and gait problems 1.4%, against none on placebo[1]. The published trial paper reports vomiting in 21.6% on rufinamide against 6.3% on placebo[6].

Across pooled epilepsy trials in children aged 3 to under 17, the most common side effects were sleepiness (17% against 9%), vomiting (17% against 7%) and headache (16% against 8%)[1]. In children aged 1 to under 4, vomiting (24%) and sleepiness (16%) were the most common, and the label says the overall pattern matched older patients[1].

Across controlled trials, 9% of people on rufinamide and 4% on placebo stopped because of a side effect[1]. Other label warnings cover suicidal thoughts and behavior, shortening of the QT interval on an ECG, a whole-body allergic reaction called DRESS, seizures or status epilepticus if the medicine is stopped suddenly, and a low white blood cell count; Stevens-Johnson syndrome and other serious rashes have been reported since approval[1]. Alcohol can add to rufinamide's effects on the brain[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Rufinamide

Banzel is taken by mouth twice a day with food, and the daily dose is split into 2 equal doses[1]. Children from 1 year to under 17 start at about 10mg/kg a day, rising by about 10mg/kg every other day to a maximum of 45mg/kg a day, never more than 3200mg a day[1]. Adults 17 and older start at 400-800mg a day, rising by 400-800mg every other day to a maximum of 3200mg a day[1]. The label says it is not known whether doses lower than these targets work[1].

People already taking valproate start rufinamide below 10mg/kg a day for children or 400mg a day for adults, because valproate can raise rufinamide levels by up to 70% in children; people already on rufinamide start valproate at a low dose[1]. Carbamazepine, phenytoin, phenobarbital and primidone lower rufinamide levels, by 19-26% for carbamazepine and 25-46% for the others[1].

The label does not recommend rufinamide in severe liver impairment and advises caution in mild or moderate liver impairment[1]. Kidney impairment needs no change, but hemodialysis removes about 30% of the drug, so the dose may be adjusted around dialysis[1]. Rufinamide is stopped gradually; in trials the dose came down by about 25% every 2 days[1].

Forms differ by product. Banzel tablets come in 200mg and 400mg pink tablets scored on both sides, and they can be swallowed whole, taken as half tablets or crushed[1]. Banzel oral suspension is an orange-flavored 40mg/mL liquid in a 460mL bottle; it is shaken well before each dose, measured with the bottle adapter and oral syringe in the carton, stored upright and used within 90 days of opening[1].

The suspension is bioequivalent to the tablets milligram for milligram, and the Medication Guide says it contains no lactose or gluten and is dye-free[1].

Availability and cost

Generic available

Generic versions may be available at a lower cost. Ask your pharmacist.

Why it costs what it costs

The label gives no price. Drugs@FDA lists 15 approved generic rufinamide applications for tablets and oral suspension, all with prescription (marketed) status[4]. Eisai's US medicines page lists Banzel but links to no savings or support program, and none was found on Eisai's reimbursement site on November 21, 2026.

Clinical trial results

The Banzel label rests on 1 double-blind trial of 138 people aged 4 to 30 with Lennox-Gastaut syndrome who had at least 90 seizures in the month before entry, including atypical absence seizures and drop attacks, while taking 1 to 3 other seizure medicines at stable doses[1][6]. After a 4-week baseline, 74 people had rufinamide and 64 had placebo added for 12 weeks, with the dose raised over 1 to 2 weeks to about 45mg/kg a day (3200mg for adults over 70kg); 88% of people on rufinamide reached that target[1].

Median total seizures fell 32.7% on rufinamide against 11.7% on placebo, and median tonic-atonic (drop) seizures fell 42.5% on rufinamide while rising 1.4% on placebo[1]. A parent or guardian rating of seizure severity also favored rufinamide, and the published paper reports that more people on rufinamide had their total and drop seizures cut by at least half[1][6].

The extension to children 1 to under 4 rests on study 303 (NCT01405053), an open-label study in which 25 children took rufinamide at 45mg/kg a day and 11 took another seizure medicine chosen by their doctor, according to the label; it showed rufinamide levels and safety similar to older patients once body weight was accounted for[1][5]. ClinicalTrials.gov lists the study as NCT01405053[7].

Development history

The FDA approved Banzel tablets on November 14, 2008 under NDA 021911, for Lennox-Gastaut seizures in people 4 years and older[2][5]. Banzel oral suspension followed on March 3, 2011 under NDA 201367[3]. On February 12, 2015 the FDA extended the label to children 1 to under 4 years old, based on a pharmacokinetic bridging study, and Eisai announced it the next day[3][5].

Drugs@FDA lists the 100mg Banzel tablet as discontinued, with a Federal Register finding that it was not withdrawn for safety or effectiveness reasons, and the 200mg and 400mg tablets remain[2]. The first generic rufinamide tablets were approved on May 16, 2016 and the first generic oral suspensions on April 23, 2019[4]. The current Banzel label on DailyMed was revised in December 2022[1].

Ask anything about Rufinamide
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Lennox-Gastaut Syndrome trials

Other Lennox-Gastaut Syndrome treatments

Common questions about Rufinamide

▸What is Rufinamide (Banzel)?

Rufinamide is a seizure medicine approved as an add-on treatment for seizures associated with Lennox-Gastaut syndrome in children 1 year and older and in adults[1]. Eisai sells it as Banzel film-coated tablets (200mg and 400mg) and Banzel oral suspension (40mg/mL)[1]. The FDA approved the tablets on November 14, 2008, the oral suspension on March 3, 2011, and the extension to children 1 to under 4 years old on February 12, 2015[2][3][5]. The label carries no boxed warning, and rufinamide is not used in people with familial short QT syndrome, an inherited heart rhythm condition[1]. Generic rufinamide tablets and oral suspension are FDA approved[4].

▸How does Rufinamide work?

Lennox-Gastaut syndrome causes several seizure types, including drop seizures (tonic or atonic seizures that can make a person fall) and atypical absence seizures (staring spells). Rufinamide is a triazole derivative, and the label says it is chemically unrelated to other marketed seizure medicines[1]. Lab studies suggest it works mainly on sodium channels, the pores nerve cells use to fire electrical signals: it keeps the channels in their resting, inactive state longer, which limits the rapid repeated firing behind seizures; the label says the exact mechanism is unknown[1]. The body breaks rufinamide down mostly through enzymes called carboxylesterases rather than the liver's cytochrome P450 system, and the breakdown products are inactive[1]. Rufinamide's half-life is about 6-10 hours, which is why it is taken twice a day, and food raises the amount absorbed by about 34%, which is why the label says to take it with food[1]. Valproate slows the clearance of rufinamide, while carbamazepine, phenytoin, phenobarbital and primidone speed it up[1].

▸What are the side effects of Rufinamide?

The Banzel label carries no boxed warning[1]. In the placebo-controlled Lennox-Gastaut trial of 74 people on rufinamide and 64 on placebo, sleepiness affected 24% against 13% and tiredness 10% against 8%, while unsteady walking (ataxia) affected 5.4%, dizziness 2.7% and gait problems 1.4%, against none on placebo[1]. The published trial paper reports vomiting in 21.6% on rufinamide against 6.3% on placebo[6]. Across pooled epilepsy trials in children aged 3 to under 17, the most common side effects were sleepiness (17% against 9%), vomiting (17% against 7%) and headache (16% against 8%)[1]. In children aged 1 to under 4, vomiting (24%) and sleepiness (16%) were the most common, and the label says the overall pattern matched older patients[1]. Across controlled trials, 9% of people on rufinamide and 4% on placebo stopped because of a side effect[1]. Other label warnings cover suicidal thoughts and behavior, shortening of the QT interval on an ECG, a whole-body allergic reaction called DRESS, seizures or status epilepticus if the medicine is stopped suddenly, and a low white blood cell count; Stevens-Johnson syndrome and other serious rashes have been reported since approval[1]. Alcohol can add to rufinamide's effects on the brain[1].

▸How is Rufinamide taken?

Banzel is taken by mouth twice a day with food, and the daily dose is split into 2 equal doses[1]. Children from 1 year to under 17 start at about 10mg/kg a day, rising by about 10mg/kg every other day to a maximum of 45mg/kg a day, never more than 3200mg a day[1]. Adults 17 and older start at 400-800mg a day, rising by 400-800mg every other day to a maximum of 3200mg a day[1]. The label says it is not known whether doses lower than these targets work[1].

People already taking valproate start rufinamide below 10mg/kg a day for children or 400mg a day for adults, because valproate can raise rufinamide levels by up to 70% in children; people already on rufinamide start valproate at a low dose[1]. Carbamazepine, phenytoin, phenobarbital and primidone lower rufinamide levels, by 19-26% for carbamazepine and 25-46% for the others[1]. The label does not recommend rufinamide in severe liver impairment and advises caution in mild or moderate liver impairment[1]. Kidney impairment needs no change, but hemodialysis removes about 30% of the drug, so the dose may be adjusted around dialysis[1]. Rufinamide is stopped gradually; in trials the dose came down by about 25% every 2 days[1].

Forms differ by product. Banzel tablets come in 200mg and 400mg pink tablets scored on both sides, and they can be swallowed whole, taken as half tablets or crushed[1]. Banzel oral suspension is an orange-flavored 40mg/mL liquid in a 460mL bottle; it is shaken well before each dose, measured with the bottle adapter and oral syringe in the carton, stored upright and used within 90 days of opening[1]. The suspension is bioequivalent to the tablets milligram for milligram, and the Medication Guide says it contains no lactose or gluten and is dye-free[1].

▸Is Rufinamide FDA approved?

Yes. The FDA approved rufinamide as Banzel tablets on November 14, 2008 and Banzel oral suspension on March 3, 2011, as an add-on treatment for seizures associated with Lennox-Gastaut syndrome, and extended it to children 1 to under 4 years old on February 12, 2015.

Who: children 1 year and older and adults with Lennox-Gastaut syndrome, alongside other seizure medicines.

Under 1: safety and effectiveness have not been established.

Not for: people with familial short QT syndrome.

Generics: generic rufinamide tablets and oral suspension are FDA approved.

Source: Banzel prescribing information and Drugs@FDA

▸What is the rufinamide dose for Lennox-Gastaut syndrome?

The dose is set by age and weight and taken in 2 equal doses a day with food[1].

Children 1 to under 17: about 10mg/kg a day to start, rising by about 10mg/kg every other day to a maximum of 45mg/kg a day, never above 3200mg a day.

Adults 17 and older: 400-800mg a day to start, rising by 400-800mg every other day to a maximum of 3200mg a day.

With valproate: the starting dose is below 10mg/kg a day for children or 400mg a day for adults.

Stopping: in trials the dose came down by about 25% every 2 days.

Source: Banzel prescribing information

▸What are the side effects of Banzel?

In the placebo-controlled Lennox-Gastaut trial, sleepiness affected 24% on rufinamide against 13% on placebo, and the published paper reports vomiting in 21.6% against 6.3%[1][6].

Other common ones: headache, tiredness, dizziness and nausea; unsteady walking (ataxia) affected 5.4% against none on placebo.

Boxed warning: none.

Serious warnings: suicidal thoughts, QT shortening on an ECG, DRESS (a whole-body allergic reaction, seen in trials in children under 12 within 4 weeks of starting), status epilepticus, and a low white blood cell count.

Skin: Stevens-Johnson syndrome and other serious rashes have been reported since approval.

Source: Banzel prescribing information and Glauser et al., Neurology 2008

▸Why does valproate change the rufinamide dose?

Valproate slows the body's clearance of rufinamide, and the label says it can raise rufinamide levels by up to 70% in children[1].

Starting rufinamide on valproate: below 10mg/kg a day for children or 400mg a day for adults.

Starting valproate on rufinamide: valproate begins at a low dose and is raised to an effective dose.

Other seizure medicines: carbamazepine, phenytoin, phenobarbital and primidone lower rufinamide levels instead.

Source: Banzel prescribing information

▸Why can't people with short QT syndrome take rufinamide?

Rufinamide shortens the QT interval, the heart's electrical recharge time between beats on an ECG, and familial short QT syndrome is the label's only contraindication[1].

How much: formal ECG studies found an average shortening of 20 milliseconds at higher doses.

Why it matters: familial short QT syndrome raises the risk of sudden death and dangerous heart rhythms, which the label says occur mainly when the corrected QT falls below 300 milliseconds.

Other people: the label says the shortening seen with rufinamide has no known clinical risk, and advises caution with other medicines that shorten the QT interval.

Source: Banzel prescribing information

▸How well did rufinamide work in Lennox-Gastaut syndrome?

In a 12-week trial of 138 people aged 4 to 30, median total seizures fell 32.7% on rufinamide against 11.7% on placebo[1].

Drop seizures: median tonic-atonic seizures fell 42.5% on rufinamide while rising 1.4% on placebo.

Severity: a parent or guardian rating of seizure severity also favored rufinamide.

Half or more fewer seizures: the published paper reports a higher share of people reaching that on rufinamide for both total and drop seizures[6].

Younger children: approval for ages 1 to under 4 rests on a study showing similar drug levels and safety.

Source: Banzel prescribing information and Glauser et al., Neurology 2008

▸Is there a generic for Banzel?

Yes. Drugs@FDA lists 15 approved generic rufinamide applications for tablets and oral suspension, the first tablets approved on May 16, 2016 and the first suspensions on April 23, 2019[4].

Eisai support: Eisai's US medicines page lists Banzel but links to no copay or patient assistance program.

Source: Drugs@FDA

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Eisai Inc. via DailyMed · 2022-12-15. BANZEL- rufinamide. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a3fa925-1abd-458a-bd57-4ae780a1ef2d
  2. U.S. Food and Drug Administration · 2008-11-14. BANZEL (rufinamide) tablets, NDA 021911. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021911
  3. U.S. Food and Drug Administration · 2011-03-03. BANZEL (rufinamide) oral suspension, NDA 201367. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201367
  4. U.S. Food and Drug Administration (openFDA) · 2026-11-21. Drugs@FDA records for rufinamide abbreviated new drug applications. https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22RUFINAMIDE%22+AND+application_number:ANDA*&limit=100
  5. Eisai Inc. · 2015-02-13. Eisai Announces FDA Approval of BANZEL® (rufinamide) for Adjunctive Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Pediatric Patients Ages 1-4. https://media-us.eisai.com/2015-02-13-Eisai-Announces-FDA-Approval-of-BANZEL-rufinamide-for-Adjunctive-Treatment-of-Seizures-Associated-with-Lennox-Gastaut-Syndrome-in-Pediatric-Patients-Ages-1-4
  6. Neurology · 2008-05-20. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. https://pubmed.ncbi.nlm.nih.gov/18401024/
  7. ClinicalTrials.gov. Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs. https://clinicaltrials.gov/study/NCT01405053
  8. Lundbeck Pharmaceuticals LLC via DailyMed · 2026-10-16. ONFI- clobazam tablet / ONFI- clobazam suspension. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de03bd69-2dca-459c-93b4-541fd3e9571c
  9. Jazz Pharmaceuticals via DailyMed · 2026-05-29. EPIDIOLEX- cannabidiol solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bf27097-4870-43fb-94f0-f3d0871d1eec
  10. UCB, Inc. via DailyMed · 2026-10-22. FINTEPLA- fenfluramine solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e88f360e-33ad-4cd6-b2de-5ef885857c5d
  11. H2-Pharma, LLC via DailyMed · 2025-12-01. KLONOPIN- clonazepam. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cfa0d79a-843c-4b88-95a1-e9511d649ca1
  12. Upsher-Smith Laboratories, LLC via DailyMed · 2026-09-03. QUDEXY XR- topiramate. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46f54677-3a22-4c38-9b92-923020164e15
  13. OWP Pharmaceuticals, Inc. via DailyMed · 2026-08-26. SUBVENITE- lamotrigine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=022b0913-f683-4af8-a862-f81b315909b2
  14. National Organization for Rare Disorders. Lennox-Gastaut Syndrome - Symptoms, Causes, Treatment. https://rarediseases.org/rare-diseases/lennox-gastaut-syndrome/
  15. Viatris Specialty LLC via DailyMed · 2025-08-15. FELBATOL- felbamate. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f522701-397a-11de-8a39-0800200c9a66

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Banzel by email

We'll email you when Banzel's FDA label changes, when the FDA acts on it, and when new trials for Lennox-Gastaut Syndrome open. Unsubscribe anytime.

You'll get, for Lennox-Gastaut Syndrome:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site